During postmarketing surveillance which includes other dosage forms and other patient populations, the following adverse events were reported. The development of diagnostic criteria has enabled greater recognition of menstrual migraine to be a highly prevalent and disabling condition meriting unique treatment. Although couple therapeutic trials ha